OncLive TV

Ricardo Costa, MD, MSc, discusses the patient population included in the phase 3 OlympiA trial in breast cancer.

John L. Marshall, MD, discusses factors to consider in the third-line treatment setting for patients with colorectal cancer.

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the importance of patient selection for cytoreductive surgery in colorectal cancer with peritoneal involvement.

Douglas W. Sborov, MD, MS, discusses the toxicities associated with novel therapies in multiple myeloma.

Pradnya D. Patil, MD, FACP, discusses the development of KRAS G12C inhibitors in lung cancer.

Steven Kaplan, MD, discusses real-world surgical retreatment rates in patients with lower urinary tract symptoms/benign prostatic hyperplasia.

Stephen B. Williams, MD, discusses the rationale for the phase 3 SunRISE-2 trial in muscle-invasive bladder cancer.

Fredrik Schjesvold, MD, PhD, discusses key takeaways from the phase 3 OCEAN trial that was done in patients with relapsed/refractory multiple myeloma.

Edward B. Garon, MD, discusses the efficacy of datopotamab deruxtecan in patients with non–small cell lung cancer, as reported in the phase 1 TROPION-PanTumor01 trial.

Raymond U. Osarogiagbon, MD, discusses geographic disparities in lung cancer mortality rates across the United States.

Michael A. Palese, MD, discusses emerging technologies in benign prostatic hyperplasia.

Ketan K. Badani, MD, discusses the utility of multiport robotic retroperitoneal partial nephrectomies in renal cell carcinoma (RCC).

Larry Anderson, MD, PhD, discusses outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma, as demonstrated in the phase 2 KarMMa trial.

Thomas G. Martin, MD, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma.

Makenzi Evangelist, MD, discusses the goals of the MYLUNG Consortium in lung cancer.

Vilde D. Haakensen, MD, PhD, discusses exclusion criteria for the Oslo University Hospital Named Patient Use program for adjuvant durvalumab in non–small cell lung cancer.

Vaishali Sanchorawala, MD, discusses the impact of renal and cardiac response on survival in patients with light chain amyloidosis. 

Nina Shah, MD, discusses the clinical implications of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Stacey A. Cohen, MD, discusses the importance of patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

Nicholas Robert, MD, discusses the importance of evaluating trends in biomarker testing in metastatic non–small cell lung cancer.

Collin Blakely MD, PhD, discusses the rationale for utilizing osimertinib in resectable EGFR-mutant non–small cell lung cancer.

Alexey V. Danilov, MD, PhD, discusses the utility of BTK inhibitors as a treatment option for patients with chronic lymphocytic leukemia.

Krina K. Patel, MD, MSc, discusses the integration of CAR T-cell therapy into the treatment paradigm of relapsed/refractory multiple myeloma.

Kanwal Raghav, MBBS, MD, discusses first-line treatment options for patients with colorectal cancer.

David Zhen, MD, discusses advancements in the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Albiruni Ryan Abdul Razak, MRCP, MBBCh, discusses initial findings from a phase 2 trial evaluating the utility of durvalumab in combination with olaparib or cediranib in leiomyosarcoma.

Neal E. Ready, MD, PhD, discusses selecting between frontline chemotherapy plus atezolizumab or durvalumab in extensive-stage small cell lung cancer.

Neehar Parikh, MD, discusses future research directions in hepatitis C-related hepatocellular carcinoma.

Josep Llovet, MD, discusses the adverse events cause by treatments in hepatocellular carcinoma.

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).